- Home
- MGX vs ACHV Comparison
MGX vs ACHV Comparison
Compare MGX & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGX
- ACHV
- Stock Information
- Founded
- MGX 2018
- ACHV N/A
- Country
- MGX United States
- ACHV Canada
- Employees
- MGX N/A
- ACHV N/A
- Industry
- MGX
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- MGX
- ACHV Health Care
- Exchange
- MGX NYSE
- ACHV Nasdaq
- Market Cap
- MGX 65.0M
- ACHV 72.5M
- IPO Year
- MGX 2024
- ACHV N/A
- Fundamental
- Price
- MGX $1.52
- ACHV $2.38
- Analyst Decision
- MGX Strong Buy
- ACHV Strong Buy
- Analyst Count
- MGX 4
- ACHV 3
- Target Price
- MGX $14.75
- ACHV $14.33
- AVG Volume (30 Days)
- MGX 354.0K
- ACHV 181.0K
- Earning Date
- MGX 05-16-2025
- ACHV 05-13-2025
- Dividend Yield
- MGX N/A
- ACHV N/A
- EPS Growth
- MGX N/A
- ACHV N/A
- EPS
- MGX N/A
- ACHV N/A
- Revenue
- MGX $52,295,000.00
- ACHV N/A
- Revenue This Year
- MGX N/A
- ACHV N/A
- Revenue Next Year
- MGX $6.95
- ACHV N/A
- P/E Ratio
- MGX N/A
- ACHV N/A
- Revenue Growth
- MGX 16.84
- ACHV N/A
- 52 Week Low
- MGX $1.23
- ACHV $1.84
- 52 Week High
- MGX $8.18
- ACHV $5.59
- Technical
- Relative Strength Index (RSI)
- MGX 49.74
- ACHV 48.90
- Support Level
- MGX $1.40
- ACHV $2.32
- Resistance Level
- MGX $1.64
- ACHV $2.69
- Average True Range (ATR)
- MGX 0.14
- ACHV 0.19
- MACD
- MGX 0.00
- ACHV 0.03
- Stochastic Oscillator
- MGX 48.52
- ACHV 64.38
About MGX METAGENOMI INC
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.